Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3436
- Registration Number
- NCT00005970
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Vermont and State Agricultural College, Burlington, Vermont, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 4312
- Registration Number
- NCT00011986
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 29
- Registration Number
- NCT00003377
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 571
- Registration Number
- NCT00003644
- Locations
- 🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
🇺🇸Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 589
- Registration Number
- NCT00004859
- Locations
- 🇺🇸
Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸Swedish Covenant Hospital, Chicago, Illinois, United States
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Target Recruit Count
- 430
- Registration Number
- NCT00011921
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
- Conditions
- Locations
- 🇫🇷
CHR de Grenoble - La Tronche, Grenoble, France
🇫🇷C.H. Senlis, Senlis, France
🇫🇷Centre Hospitalier Regional Metz Thionville, Thionville, France
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 154
- Registration Number
- NCT00026104
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 28
- Registration Number
- NCT00004924
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Northwestern Connecticut Oncology-Hematology Associates - Torrington, Torrington, Connecticut, United States
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00031694
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.